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MATERIALS AND METHODS
Mixtures of olanzapine and L-arginine and L-tryptophan (1:1) and paroxetin and L-arginine, L-tryptophan, L-proline, L-lysine, L-tyrosine
and L-phenylalanine (1:1) were processed by ball milling and quench cooling. The new products were characterized by Differential
Scanning Calorimetry (DSC) in order to identify the formation of co-amorphous between each drug and the amino acid.
DSC is a calorimetric analytical technique that looks at how a material’s heat capacity (Cp) is affected by temperature. A sample of
known mass is heated or/and cooled and the changes in its heat capacity are tracked as changes in the heat flow. This allows the
detection of transitions such as melts (Tm) and glass transitions (Tg).
RESULTS AND DISCUSSION
Results have shown that olanzapine seems to be converted into the amorphous state in combination with arginine or tryptophan, either
by quench cooling, or ball milling (Fig 1 and 2, respectively). Olanzapine alone became amorphous by quench cooling and by milling
too, like paroxetine. Paroxetine was converted into the amorphous form when in combination with the amino acid L-proline (Fig 3).
INTRODUCTION
Orally administered drugs must have sufficient water solubility to ensure that they are absorbed in the gut, as required for
bioavailability and therapeutic activity. As the number of poorly water soluble drug molecules entering the clinic rises, the strategies
to enhance solubility also become increasingly important. Conversion of a crystalline drug into the amorphous form is one way to
improve its apparent solubility and dissolution rate (a measure of bioavailability). Unfortunately, the large internal energy and
molecular movement of the molecules in the amorphous state may also cause the material to convert spontaneously back to its stable
crystalline form during processing, storage or dissolution (1,2). Co-amorphous structures containing one, or more, small molecular
weight compounds, which are homogenously mixed to form a new entity with a single amorphous phase (2,3), have been shown to
stabilize the amorphous form of a drug in the solid state (2). Finding low molecular weight excipients compatible with the model drug
may, however, be challenging (3). In this respect, amino acids have proved their potential to form co-amorphous systems with some
drugs and are the object of the present work (1,2). Different techniques are available to obtain co-amorphous systems, namely ball
milling or quench cooling, since these techniques inflict limited chemical degradation to the drug (1,2).
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CONCLUSION
The study has shown that the conversion of crystalline drugs into the amorphous state is dependent on their chemical structures and
interactions with other chemical entities. For the model drugs studied the use of specific amino acids, in combination with the
appropriate processing technique, has confirmed the potential to form co-amorphous systems. The use of amino acids seems to be a
promising approach, worth to be explored further, provided the right combination (drug:amino acid) and processing technique have
been identified.
Fig 2 – Thermogram of the co-amorphous olanzapine and 
L-tryptophan produced by ball milling (6h at 650rpm)
Fig 1 – Thermogram of the co-amorphous olanzapine and 
L-arginine produced by quench cooling
Fig 3 – Thermogram of the co-amorphous paroxetine and 
L-proline produced directly on the DSC
1st run – heating         and cooling
2nd run – heating        and cooling
Recrystallization events are circled in green
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